These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22829536)

  • 1. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.
    Lingg N; Zhang P; Song Z; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1462-72. PubMed ID: 22829536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological significance of glycosylation in therapeutic proteins.
    Li H; d'Anjou M
    Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of glycosylation analysis in development of biopharmaceuticals.
    Kawasaki N; Itoh S; Hashii N; Takakura D; Qin Y; Huang X; Yamaguchi T
    Biol Pharm Bull; 2009 May; 32(5):796-800. PubMed ID: 19420744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large scale production of recombinant human lactoferrin in the milk of transgenic cows.
    van Berkel PH; Welling MM; Geerts M; van Veen HA; Ravensbergen B; Salaheddine M; Pauwels EK; Pieper F; Nuijens JH; Nibbering PH
    Nat Biotechnol; 2002 May; 20(5):484-7. PubMed ID: 11981562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human rhabdomyosarcoma cell line TE671--Towards an innovative production platform for glycosylated biopharmaceuticals.
    Rosenlöcher J; Weilandt C; Sandig G; Reinke SO; Blanchard V; Hinderlich S
    Protein Expr Purif; 2015 Nov; 115():83-94. PubMed ID: 26272370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new large-scale manufacturing platform for complex biopharmaceuticals.
    Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
    Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the glycosylation state of therapeutic recombinant glycoproteins.
    Samuels N; Kates D; Liu J; Severs J
    Methods Mol Biol; 2013; 951():323-34. PubMed ID: 23296541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the quality and structural integrity of a complex glycoprotein mixture following extraction from the formulated biopharmaceutical drug product.
    Liu C; Dong S; Xu XJ; Yin Y; Shriver Z; Capila I; Myette J; Venkataraman G
    J Pharm Biomed Anal; 2011 Jan; 54(1):27-36. PubMed ID: 20800406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the glycosylation patterns of recombinant glycoproteins.
    Parekh RB; Patel TP
    Trends Biotechnol; 1992 Aug; 10(8):276-80. PubMed ID: 1368380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants.
    Parsons J; Altmann F; Arrenberg CK; Koprivova A; Beike AK; Stemmer C; Gorr G; Reski R; Decker EL
    Plant Biotechnol J; 2012 Sep; 10(7):851-61. PubMed ID: 22621344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycan analysis of glycoprotein pharmaceuticals: Evaluation of analytical approaches to Z number determination in pharmaceutical erythropoietin products.
    Yuen CT; Zhou Y; Wang QZ; Hou JF; Bristow A; Wang JZ
    Biologicals; 2011 Nov; 39(6):396-403. PubMed ID: 21993307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of recombinant vaccines and antibodies in plants.
    Ko K
    Monoclon Antib Immunodiagn Immunother; 2014 Jun; 33(3):192-8. PubMed ID: 24937251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in therapeutic glycoprotein production.
    Sethuraman N; Stadheim TA
    Curr Opin Biotechnol; 2006 Aug; 17(4):341-6. PubMed ID: 16828275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of glycoforms on the glycosylation site and the glycans in monoclonal antibody biopharmaceuticals.
    Uçaktürk E
    J Sep Sci; 2012 Feb; 35(3):341-50. PubMed ID: 22213703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of N-linked glycosylation on recombinant glycoproteins produced in Pichia pastoris using ESI-MS and MALDI-TOF.
    Gong B; Cukan M; Fisher R; Li H; Stadheim TA; Gerngross T
    Methods Mol Biol; 2009; 534():213-23. PubMed ID: 19277549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-based production of biopharmaceuticals.
    Fischer R; Stoger E; Schillberg S; Christou P; Twyman RM
    Curr Opin Plant Biol; 2004 Apr; 7(2):152-8. PubMed ID: 15003215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.